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INTRODUCTION
The incidence of bone metastases is high among patients 
with advanced cancer. Bone metastases occur in about 80% 
of men with advanced prostate cancer,1 75% of patients with 
metastatic breast cancer2 and 30% to 60% of patients with 
advanced metastatic lung cancer,3 and are present in 35% of 
patients with renal cell carcinoma at the time of diagnosis4.
Bone metastases cause considerable skeletal morbidity 
with severe bone pain in some cases, pathologic fractures, 
spinal cord compression and hypercalcemia. In addition, 
patients frequently need radiotherapy or surgery to treat 
bone pain or to prevent pathological fractures.3,5 Because of 
this, complications from bone metastases heavily impact the 
quality of life of patients with cancer. Therefore, the preven-
tion or delay of these complications would be of significant 
benefit to patients with advanced cancer.6
The bisphosphonates represent a major advance in help-
ing patients with bone metastases.7 They have been largely 
used in the treatment of this condition, since they inhibit 
osteoclastic activity, proliferation of tumor cells and angio-
genesis. Bisphosphonates are also used in the treatment of 
other bone diseases, such as osteoporosis, Paget’s disease 
and malignancy-related hypercalcemia.8-10
In 1995, intravenous pamidronate was approved for 
treating patients with multiple myeloma or metastatic breast 
cancer based on study findings that pamidronate reduces the 
risk of skeletal complications. In 2002, intravenous zole-
dronic acid was approved for the treatment and prevention of 
skeletal complications in patients with multiple myeloma or 
with bone metastases from any solid tumor type.11,12 This was 
the first bisphosphonate with proven efficacy in the treatment 
of bone metastases from solid tumors, in addition to breast 
carcinoma.6 Currently, therapy with bisphosphonates is con-
sidered standard in the prevention of skeletal complications 
in patients with bone metastases.13
Although serious side-effects have been reported, includ-
ing acute renal failure after intravenous administration and 
gastrointestinal toxicities such as esophagitis when used 
orally, these drugs are generally well tolerated14. Recently, 
however, a new complication associated with the use of 
bisphosphonates has been described: osteonecrosis of the 
jaw. This condition was initially associated with the use of 
zoledronic acid, but occurrences after pamidronate use have 
also been reported.15, 16 
CASE REPORT
A 57-year-old male patient sought medical help for pro-
gressive lumbar pain. Tomographic studies revealed lytic 
lesions in L1, L2 and L3, and a hypodense lobulated mass 
in the left kidney. The patient underwent radiotherapy on 
the lumbar column, followed by a left nephrectomy (renal 
clearance after this procedure was 80 mL/min) and treatment 
with 5 MU/m² interferon, three times a week, and 4 mg of 
intravenous zoledronic acid administered as a 15-minute in-
fusion every 4 weeks. After one year of therapy with no evi-
dence of active disease, the patient required invasive dental 
treatment due to intense pain in his left molar tooth. Fifteen 
days after this procedure, he developed an ulcerated lesion 
in his lower jaw with local purulent secretion (Figure 1). In a 
radiological evaluation, osteonecrosis with bone rarefaction 
in the regional jaw was discovered (Figure 2).
Figure 1 - Ulcered jaw lesion with local purulent secretion due to osteone-
crosis after zoledronic acid treatment282
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DISCUSSION
Bisphosphonates are analogous to synthetic pyro-
phosphate, a natural regulator of bone metabolism that is 
abundant in the bone matrix.17 These compounds inhibit the 
differentiation of osteoclastic precursors, lead to osteoclast 
apoptosis and stimulate the release of osteoclastic inhibitory 
factor from osteoblasts.18 Numerous clinical studies have 
shown that bisphosphonates can reduce the incidence of 
pathological fractures, bone pain, episodes of hypercalcemia 
and the need for radiotherapy and surgery in patients with 
osteolytic bone metastases.19-21
In addition to adverse effects previously associated with 
the use of bisphosphonates, a new complication has recently 
been described: avascular osteonecrosis of the jaw.15,16,22-24 
The incidence of this complication is around 0.03% to 6.2%. 
This variation mainly depends on the type of analysis.16,22,25 
Osteonecrosis has been associated with a wide range of condi-
tions, including corticosteroid usage, alcoholism, infections, 
hyperbaric events, storage disorders, marrow infiltrating 
diseases, coagulation defects and some autoimmune diseases. 
However, a large number of idiopathic cases of osteonecrosis 
have been described without an obvious etiologic factor.26 
The osteoclastic function is part of the cycle of bone 
turnover. If osteoclastic function is too severely impaired, 
dead and dying osteocytes are not replaced, and the capillary 
network in the bone is not maintained, resulting in avascular 
bone necrosis.27
Zoledronic acid was the most powerful bisphosphonate 
investigated in pre-clinical tests of bone resorption.7 How-
ever, extended treatments with bisphosphonates increase the 
risk of osteonecrosis, which is greater with the use of zole-
dronic acid than with the use of pamidronate in treatments 
exceeding 36 months.28,29
Reports have shown that the majority of patients (69%) 
had teeth pulled before the development of osteonecrosis. 
This seems to confirm the importance of this type of trauma 
in causing the complication,30 and can be explained by the 
fact that when local defenses are overwhelmed by infection, 
trauma or surgery, diverse microorganisms may invade the 
bone marrow. Additionally, the inhibition of angiogenesis 
can aggravate this process by compromising the vascular 
supply through tissue cicatrisation.31
A study that included 225 patients showed that the most 
common symptom of osteonecrosis is pain (94), followed 
by purulent secretion (10), oroanthral fistula (7), swelling 
(3) and fever (1). Data was available for only 115 (51.1%) 
of these patients. In 14 other patients (12.2%), osteonecro-
sis was asymptomatic and was discovered through routine 
tests.30
Therefore, to avoid osteonecrosis of the jaw, it is recom-
mended that patients who are about to start bisphosphonate 
therapy have a complete dental exam in order to identify 
possible existing infections, compromised teeth and dentures 
that do not fit properly. If therapy with bisphosphonates can 
be delayed, preventive surgery to eliminate possible infec-
tions must be performed. In addition, any jaw or elective 
maxillary procedure requiring healing should be avoided. 
Proper dental health during treatment is crucial, and all 
patients should be informed of the importance of good oral 
hygiene. In addition, a regular visual inspection by an oncol-
ogist and a routine evaluation by a dentist are important.30
Figure 2 - Panoramic x-ray showing bisphosphonate-induced osteonecrosis in the left jaw283
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If osteonecrosis develops, non-surgical access can 
achieve benefits through antibiotic therapy. Interruption of 
bisphosphonate therapy can be considered in severe cases if 
the benefits outweigh the risks of skeletal events, although 
no improvements have been observed in cases published 
so far.31 Similarly, therapy with hyperbaric oxygen did not 
prove to be effective.30
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